Tisagenlecleucel (Kymriah, Novartis) and axicabtagen ciloleucel (Yescarta, Kite/Gilead) are both anti-CD19 CAR T-cell (CART19) commercial products that obtained Food and Drug Administration (FDA) approval in 2017 for the treatment of pediatric and young adult patients with CD19+ relapsed/refractory B-cell ALL, relapsed/refractory B-cell NHL [diffuse large B-cell lymphoma (DLBCL), primary mediastinal B-cell lymphoma and transformed follicular lymphoma]. Here, CD19 is linked to diffuse large B-cell lymphoma.